Invention Grant
- Patent Title: PDE9 inhibitor and use thereof
-
Application No.: US17141385Application Date: 2021-01-05
-
Publication No.: US11434248B2Publication Date: 2022-09-06
- Inventor: Frank Wu , Lin Li , Xiaoju Yang
- Applicant: Nanjing TransThera Biosciences Co. Ltd.
- Applicant Address: CN Nanjing
- Assignee: Nanjing TransThera Biosciences Co. Ltd.
- Current Assignee: Nanjing TransThera Biosciences Co. Ltd.
- Current Assignee Address: CN Nanjing
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Wei Song
- Priority: CN201710900197.8 20170928,CN201810203538.0 20180313,CN201810871998.0 20180802
- Main IPC: C07D491/107
- IPC: C07D491/107 ; C07D471/04 ; C07D519/00

Abstract:
The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.
Public/Granted literature
- US20210130366A1 PDE9 INHIBITOR AND USE THEREOF Public/Granted day:2021-05-06
Information query